

# ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent

Torreya advised ERYTECH on the transaction

Cambridge, MA and Lyon, France, April 25th, 2022

ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced the sale of its U.S. manufacturing facility to Catalent, a leading contract development and manufacturing organization (CDMO) in advanced therapies.

Under the terms of an asset purchase agreement between ERYTECH and Catalent, Catalent agreed to acquire ERYTECH's state-of-the-art commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, for a total consideration of \$44.5 million. ERYTECH's current staff at the site of approximately 40 people will be offered Catalent's employment.

The parties will also enter into a long-term supply agreement, under which Catalent will manufacture ERYTECH's lead product candidate eryaspase (GRASPA®) for clinical and commercial supply in the United States. ERYTECH has a Phase 1 trial in first-line pancreatic cancer ongoing in the United States and is in a continued dialogue with the U.S. FDA regarding a potential BLA submission for GRASPA® in hypersensitive ALL, now targeted in the third quarter of 2022, subject to FDA agreement on remaining outstanding information requests.

Catalent will also offer their expertise in late-stage and commercial manufacturing of advanced therapy medicinal products with respect to product characterization, commercial production, regulatory inspections, and approvals.

Torreya advised ERYTECH on this transaction, which highlights Torreya's strength in the biopharma and CDMO sectors.

## ABOUT ABOUT ERYTECH PHARMA:

For more information about ERYTECH, please see: [www.erytech.com](http://www.erytech.com)

## ABOUT CATALENT:

For more information about Catalent, please see: [www.catalent.com](http://www.catalent.com)

## Deal Press Release

### Torreya Contacts

#### STEPHANIE LÉOUZON

Partner and Head of Torreya Europe | London Office

[stephanie.leouzon@torreya.com](mailto:stephanie.leouzon@torreya.com) | +44 (0) 207-451-4553 | [BIO](#)

#### KELLY CURTIN

Managing Director | London Office

[kelly.curtin@torreya.com](mailto:kelly.curtin@torreya.com) | +44 (0) 207-451-4564 | [BIO](#)

#### PING SHEK

Managing Director | London Office

[ping.shek@torreya.com](mailto:ping.shek@torreya.com) | +44 (0) 207-451-4552 | [BIO](#)

Torreya is a global advisory firm serving the life sciences industry. Please visit [torreya.com](http://torreya.com) for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 15 Stratford Place, London W1C 1BE. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.



Sale of U.S. manufacturing facility and long-term supply agreement with



**\$44.5 million**  
April 2022